Aumed, a.s., Komořanská 326/63, 143 14 Praha - Modřany, Česká republika

+420 603 587 701 English

WE DEVELOP NEW IMMUNOBIOLOGICAL PRODUCTS AND INNOVATIVE MEDICINES

ABOUT COMPANY

AUMED a.s. was established in 2007. Its original focus has gradually begun to focus on the healthcare and pharmaceutical industries, where research and development activities are absolutely necessary due to new market requirements.

AUMED A.S. HAS PARTICIPATED IN THE FIGHT AGAINST THE PANDEMIC OF COVID-19

In cooperation with Protean s.r.o. and Institute of Molecular and Translational Medicine, AUMED a.s. launched a modern diagnostics of SARS-CoV-2 virus under the name AUMED test RT-LAMP Assay SARS-CoV-2. AUMED, a.s. also launched a new self-sampling PCR GARGLING KIT, the principle of which is based on gargling of the oral cavity and pharynx.

NEWS

Successful completion of the TRIO project „Development of a new dosage form for oral vaccine administration”

18. 05. 2022

AUMED, a.s. successfully completed a multi-year project of the research and development support program of the Ministry of Industry and...

AUMED, a.s. received a grant for the Innovation Project entitled “TFI Transfer Factor – Medicinal Product”

18. 05. 2022

AUMED, a.s. received a grant in the Operational Program Enterprise and Innovation for Competitiveness under the Innovation Call – Innovation...

Research projects of Aumed, a.s. are financed by the European Structural Funds:
Research and development of a new pertussis vaccine
Transfer factor — research and development of a new medical form
Production of diagnostic kit for covid-19 on the lamp principle

and with financial support from the state budget through the Ministry of Industry and Trade in the TRIO program:
Research and development of a new oral administration of vaccine

European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness


Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s